Thanks to the shrill buzz around artificial intelligence, the unmatched potential of the biotech industry largely goes unnoticed. Yet, the opportunity is huge, with the market already reaching a mammath $1.55 trillion in 2023. Experts project it will further grow to $3.88 trillion by 2030.
Within this huge and growing opportunity, the savviest investors are looking for rare biotech companies that specialize in treating mental health conditions. One such biotech gem is California-based Vistagen Therapeutics (VTGN).
